NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Price Target & More

$5.70 +0.28 (+5.17 %)
(As of 04/19/2018 07:30 AM ET)
Previous Close$5.42
Today's Range$5.33 - $5.82
52-Week Range$4.78 - $15.19
Volume39,400 shs
Average Volume62,915 shs
Market Capitalization$57.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

About Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics logoArcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARCT
CUSIPN/A
Phone972-72-220-4661

Debt

Debt-to-Equity RatioN/A
Current Ratio17.64%
Quick Ratio17.64%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$12.00 per share
Price / Book0.48

Profitability

EPS (Most Recent Fiscal Year)($6.23)
Net Income$-24,600,000.00
Net MarginsN/A
Return on Equity-36.83%
Return on Assets-34.70%

Miscellaneous

Employees19
Outstanding Shares10,690,000

How to Become a New Pot Stock Millionaire

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.02. View Arcturus Therapeutics' Earnings History.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Arcturus Therapeutics.

What price target have analysts set for ARCT?

5 analysts have issued 1 year target prices for Arcturus Therapeutics' shares. Their predictions range from $1.00 to $12.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $4.0625 in the next year. View Analyst Ratings for Arcturus Therapeutics.

Who are some of Arcturus Therapeutics' key competitors?

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the folowing people:
  • Dr. Stuart J. M. Collinson, Exec. Chairman (Age 58)
  • Mr. Mark R. Herbert, Interim Pres
  • Mr. Joseph E. Payne M.Sc., Founder
  • Ms. Rebecque J. Laba, VP of Fin. & Operations (Age 57)
  • Dr. Christine Esau, VP of R&D

Has Arcturus Therapeutics been receiving favorable news coverage?

News coverage about ARCT stock has trended very positive this week, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arcturus Therapeutics earned a news sentiment score of 0.53 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $5.70.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $57.95 million. The biotechnology company earns $-24,600,000.00 in net income (profit) each year or ($6.23) on an earnings per share basis. Arcturus Therapeutics employs 19 workers across the globe.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor, Tel Aviv L3, 6701101. The biotechnology company can be reached via phone at 972-72-220-4661 or via email at [email protected]


MarketBeat Community Rating for Arcturus Therapeutics (ARCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arcturus Therapeutics (NASDAQ:ARCT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Their average twelve-month price target is $4.0625, suggesting that the stock has a possible downside of 28.73%. The high price target for ARCT is $12.00 and the low price target for ARCT is $1.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.332.402.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.0625$3.45$1.3125$1.6071
Price Target Upside: 28.73% downside38.61% downside84.93% downside53.06% upside

Arcturus Therapeutics (NASDAQ:ARCT) Consensus Price Target History

Price Target History for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2018Ladenburg ThalmannDowngradeBuy -> NeutralLowView Rating Details
1/22/2018Chardan CapitalInitiated CoverageBuy -> Buy$12.00HighView Rating Details
10/9/2017WBB SecuritiesUpgradeHold -> Buy$2.00N/AView Rating Details
9/29/2017Roth CapitalDowngradeBuy -> Neutral$4.00 -> $1.00LowView Rating Details
6/12/2017Jefferies GroupReiterated RatingHold$1.25LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00LowView Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/AView Rating Details
1/17/2017OppenheimerReiterated RatingHoldN/AView Rating Details
1/17/2017Piper JaffraySet Price TargetHold$3.00 -> $2.00N/AView Rating Details
10/28/2016BarclaysDowngradeEqual Weight -> Underweight$3.00 -> $2.00N/AView Rating Details
9/1/2016Goldman SachsReiterated RatingBuyN/AView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Arcturus Therapeutics (NASDAQ:ARCT) Earnings History and Estimates Chart

Earnings by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.81 EPS
Next Year EPS Consensus Estimate: $-2.05 EPS

Arcturus Therapeutics (NASDAQ ARCT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018        
11/9/2017Q3 2017($0.56)($0.63)ViewN/AView Earnings Details
8/11/20176/30/2017($0.15)($0.13)ViewN/AView Earnings Details
5/30/20173/31/2017($0.15)($0.13)ViewN/AView Earnings Details
2/15/201712/31/2016($0.26)($0.22)ViewListenView Earnings Details
11/15/2016Q316($0.27)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/12/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015Q1 2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.61)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.58)($0.57)ViewListenView Earnings Details
5/15/2014Q1 2014($3.22)$3.99ViewN/AView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
5/7/2012$0.18$0.14ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arcturus Therapeutics (NASDAQ:ARCT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/28/2012monthly$0.05966.21%1/4/20131/8/20131/15/2013
12/27/2012jan 13$0.05961/8/20131/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Arcturus Therapeutics (NASDAQ ARCT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.02%
Institutional Ownership Percentage: 9.24%
Insider Trading History for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ ARCT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Arcturus Therapeutics (NASDAQ ARCT) News Headlines

Source:
DateHeadline
Arcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder AccountabilityArcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability
finance.yahoo.com - April 13 at 5:06 PM
Arcturus Therapeutics (ARCT) Receives Consensus Recommendation of "Hold" from AnalystsArcturus Therapeutics (ARCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 31 at 1:36 AM
Health Care Sector Update for 03/28/2018: ARCT,SHPG,BKD,APRI,NSPRHealth Care Sector Update for 03/28/2018: ARCT,SHPG,BKD,APRI,NSPR
www.nasdaq.com - March 29 at 5:02 PM
BRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph PayneBRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph Payne
www.reuters.com - March 28 at 9:02 AM
Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus ShareholdersArcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders
finance.yahoo.com - March 28 at 9:02 AM
Arcturus Therapeutics Announces Extraordinary General Meeting of ShareholdersArcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
finance.yahoo.com - March 19 at 8:56 AM
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach - GlobeNewswire (press release)Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:53 AM
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board OutreachArcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach
finance.yahoo.com - March 6 at 8:44 AM
Arcturus Therapeutics Ltd (ARCT) Given Average Recommendation of "Hold" by AnalystsArcturus Therapeutics Ltd (ARCT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 6 at 1:36 AM
Arcturus Therapeutics (ARCT) Cut to "Neutral" at Ladenburg Thalmann Financial ServicesArcturus Therapeutics (ARCT) Cut to "Neutral" at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - March 1 at 12:30 AM
BRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholdersBRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders
www.reuters.com - February 27 at 8:50 AM
Head-To-Head Comparison: Aerie Pharmaceuticals (AERI) versus Arcturus Therapeutics (ARCT)Head-To-Head Comparison: Aerie Pharmaceuticals (AERI) versus Arcturus Therapeutics (ARCT)
www.americanbankingnews.com - February 26 at 1:22 PM
Arcturus Therapeutics Comments on Amended 13D FilingArcturus Therapeutics Comments on Amended 13D Filing
finance.yahoo.com - February 16 at 8:40 AM
Active-Investors: Wired News - Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of R&DActive-Investors: Wired News - Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of R&D
www.finanznachrichten.de - February 15 at 5:01 PM
BRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus TherapeuticsBRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics
www.reuters.com - February 13 at 4:02 PM
Arcturus Therapeutics Ltd (ARCT) Given Consensus Rating of "Hold" by AnalystsArcturus Therapeutics Ltd (ARCT) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 9 at 1:30 AM
40 Biggest Movers From Friday | Benzinga - Benzinga40 Biggest Movers From Friday | Benzinga - Benzinga
www.benzinga.com - February 5 at 4:00 PM
Arcturus Therapeutics (ARCT) and Its Rivals Financial ComparisonArcturus Therapeutics (ARCT) and Its Rivals Financial Comparison
www.americanbankingnews.com - February 3 at 1:28 PM
Arcturus Therapeutics Appoints Mark Herbert as Interim President - GlobeNewswire (press release)Arcturus Therapeutics Appoints Mark Herbert as Interim President - GlobeNewswire (press release)
globenewswire.com - February 2 at 4:07 PM
Arcturus Therapeutics Appoints Mark Herbert as Interim PresidentArcturus Therapeutics Appoints Mark Herbert as Interim President
finance.yahoo.com - February 2 at 9:36 AM
Chardan Capital Begins Coverage on Arcturus Therapeutics (ARCT)Chardan Capital Begins Coverage on Arcturus Therapeutics (ARCT)
www.americanbankingnews.com - January 22 at 8:10 AM
Comparing Arcturus Therapeutics (ARCT) & Its PeersComparing Arcturus Therapeutics (ARCT) & Its Peers
www.americanbankingnews.com - January 20 at 1:10 AM
Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI DisordersArcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders
finance.yahoo.com - January 17 at 11:11 AM
Arcturus Therapeutics Ltd (ARCT) Given Average Recommendation of "Hold" by BrokeragesArcturus Therapeutics Ltd (ARCT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM
Contrasting Arcturus Therapeutics (ARCT) & The CompetitionContrasting Arcturus Therapeutics (ARCT) & The Competition
www.americanbankingnews.com - January 10 at 12:12 PM
Arcturus Therapeutics (ARCT) & Its Rivals Critical AnalysisArcturus Therapeutics (ARCT) & Its Rivals Critical Analysis
www.americanbankingnews.com - January 7 at 11:26 PM
Head-To-Head Survey: Aclaris Therapeutics (ACRS) versus Arcturus Therapeutics (ARCT)Head-To-Head Survey: Aclaris Therapeutics (ACRS) versus Arcturus Therapeutics (ARCT)
www.americanbankingnews.com - January 7 at 1:10 AM
A Peek Into The Markets: US Stock Futures Surge Ahead Of Economic Reports - BenzingaA Peek Into The Markets: US Stock Futures Surge Ahead Of Economic Reports - Benzinga
www.benzinga.com - January 4 at 8:19 AM
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid ... - Business Wire (press release)CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid ... - Business Wire (press release)
www.businesswire.com - January 4 at 8:19 AM
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA TherapeuticsCureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
finance.yahoo.com - January 4 at 8:19 AM
Arcturus Therapeutics Ltd (ARCT) Given Consensus Recommendation of "Hold" by BrokeragesArcturus Therapeutics Ltd (ARCT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 21 at 2:04 AM
Alcobra (ARCT) vs. Trevena (TRVN) Critical ComparisonAlcobra (ARCT) vs. Trevena (TRVN) Critical Comparison
www.americanbankingnews.com - December 12 at 11:08 AM
Alcobra (ARCT) Receives New Coverage from Analysts at Ladenburg Thalmann Financial ServicesAlcobra (ARCT) Receives New Coverage from Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - November 29 at 8:12 PM
Alcobra Ltd. (ARCT) Receives Consensus Rating of "Hold" from BrokeragesAlcobra Ltd. (ARCT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 26 at 1:38 AM
Should You Buy Alcobra Ltd (ARCT)?Should You Buy Alcobra Ltd (ARCT)?
finance.yahoo.com - November 20 at 1:51 PM

SEC Filings

Arcturus Therapeutics (NASDAQ:ARCT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arcturus Therapeutics (NASDAQ:ARCT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arcturus Therapeutics (NASDAQ ARCT) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.